

ITL Limited 2018 Annual General Meeting –Results of Meeting

I advise that the outcome of voting at ITL's AGM on 26 October 2018 were as follows:

Resolution 1 – Adoption of the remuneration report

The resolution was passed by a show of hands at the meeting.

The proxy votes received for the resolution were:

For: 6,265,457 (including open votes voted by the chair for)

Against: 666,195

Total 6,931,652

Resolution 2 –Re-election of Mr William Mobbs as a Director

The resolution was passed by a show of hands at the meeting.

The proxy votes received for the resolution were:

For: 44,424,417

Against: 246,972

Total 44,671,389

Resolution 3 – Approval of on-market share buyback

The resolution was passed by a show of hands at the meeting.

The proxy votes received for the resolution were:

For: 44,069,439

Against: 651,950

Total 44,721,389

Resolution 4 – Approval of Additional 10% Placement Capacity

The resolution was passed by a show of hands at the meeting.

The proxy votes received for the resolution were:

For: 43,977,454

Against: 579,695

Total 44,557,149

ITL Health Group

ITL is an innovative global medical technology company comprising two divisions; ITL BioMedical and MyHealthTest. ITL holds an IP portfolio of more than 50 patents and sells into 55 countries.

ITL BioMedical creates and manufactures leading edge medical devices for the global blood industry including products for the clinical, blood banking, and laboratory markets. ITL is a growing provider of specialist ancillary products for the Blood Culture Testing and Blood Stream Infection Prevention markets.

MyHealthTest is developing a disruptive business model in the pathology testing market and is building an innovative platform for driving and leveraging the direct to consumer healthcare revolution.



Ranked 16th most Innovative Company by the
AFR Innovative Companies Awards

Australian Securities Exchange

Code: ITD

Ordinary Shares

85,552,339

Board of Directors

Bill Mobbs	Executive Chairman
Mark Peatey	Non-executive Director
Andrew Turnbull	Non-executive Director

Trevor Doolan	Chief Financial Officer & Company Secretary
---------------	--

ITL Contact

Trevor Doolan	Company Secretary
Phone:	+61 3 9088 7991
Email:	info@itlhealthgroup.com
Address:	Level 3, 10 Moore Street, Canberra, ACT 2601

www.itlhealthgroup.com

Media

Walbrook IR	Ben Knowles
Phone:	+61 426 277 760
Email:	ben.knowles@walbrookir.co.au

Resolution 5 – Appointment of Nexia Sydney Auditors P/L to ITL Health Group Limited

The resolution was passed by a show of hands at the meeting.

The proxy votes received for the resolution were:

For: 44,167,223

Against: 157,827

Total 44,325,050

Yours faithfully
ITL Health Group Limited

A handwritten signature in black ink, appearing to be 'Trevor Doolan', with a stylized flourish at the end.

Trevor Doolan
Company Secretary

About ITL Health Group www.itlhealthgroup.com

ITL is an innovative global medical technology company comprising two divisions; ITL BioMedical and MyHealthTest. ITL holds an IP portfolio of more than 50 patents and sells into 55 countries.

ITL BioMedical creates and manufactures leading edge medical devices for the global blood industry including products for the clinical, blood banking, and laboratory markets. ITL is a growing provider of specialist ancillary products for the Blood Culture Testing and Blood Stream Infection Prevention markets.

MyHealthTest is developing a disruptive business model in the pathology testing market and is building an innovative platform for driving and leveraging the direct to consumer healthcare revolution.